Cargando…

Assessing SARS-CoV-2 Antigen Specific T-cell Responses After mRNA Vaccination and/or Omicron Variant COVID-19 Infection in Patients with Primary Humoral Immunodeficiencies

Detalles Bibliográficos
Autores principales:	Sanchez, David, Radigan, Lin, Cunningham-Rundles, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Mosby, Inc. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895881/ http://dx.doi.org/10.1016/j.jaci.2022.12.610

Ejemplares similares

Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease
por: Bitzenhofer, Michaela, et al.
Publicado: (2022)

Circulating bioactive bacterial DNA is associated with immune activation and complications in common variable immunodeficiency
por: Ho, Hsi-en, et al.
Publicado: (2021)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
por: Zhang, Na-Na, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Immunodeficiency and Mucosal Immunity
por: Cunningham-Rundles, Charlotte
Publicado: (2005)

Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
por: Storti, Paola, et al.
Publicado: (2022)

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
por: Nanishi, Etsuro, et al.
Publicado: (2022)

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
por: Zhang, Biyan, et al.
Publicado: (2022)

Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine
por: Saharia, Kapil K, et al.
Publicado: (2022)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

SARS-CoV-2 mRNA Vaccine Elicits Sustained T Cell Responses Against the Omicron Variant in Adolescents
por: Choi, Sujin, et al.
Publicado: (2023)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

P850: THE HUMORAL AND CELLULAR RESPONSE TO SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA AND PRE-MALIGNANT MONOCLONAL GAMMOPATHIES: IMPACT OF OMICRON VARIANT
por: Storti, P., et al.
Publicado: (2022)

The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination
por: Hastert, Florian D., et al.
Publicado: (2022)

Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients
por: Ovcar, Eugen, et al.
Publicado: (2023)

Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China
por: Zeng, Qing-Lei, et al.
Publicado: (2022)

Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
por: Gray, Ashley N., et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
por: Edara, Venkata-Viswanadh, et al.
Publicado: (2022)

Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
por: Lu, Changrui, et al.
Publicado: (2023)

Seeking Relevant Biomarkers in Common Variable Immunodeficiency
por: Ho, Hsi-en, et al.
Publicado: (2022)

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
por: Lee, I-Jung, et al.
Publicado: (2022)

Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review
por: Chen, Zhonghao, et al.
Publicado: (2022)

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients
por: Alcheikh, Ahmad, et al.
Publicado: (2023)

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
por: Garcia-Beltran, Wilfredo F., et al.
Publicado: (2021)

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
por: Garcia-Beltran, Wilfredo F., et al.
Publicado: (2022)

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders
por: Harrington, Patrick, et al.
Publicado: (2022)

mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern
por: Wang, Gang, et al.
Publicado: (2022)

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
por: Scheaffer, Suzanne M., et al.
Publicado: (2022)

Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting
por: Batra, Gaurav, et al.
Publicado: (2023)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease
por: Stich, Maximilian, et al.
Publicado: (2022)

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
por: Mairhofer, Mario, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
por: Strengert, Monika, et al.
Publicado: (2021)

Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
por: Oyaert, Matthijs, et al.
Publicado: (2022)

Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_31i4amu0snpa73kjbomqte2ad5